Kite, a Gilead Company , today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the previous ...
Leaks and Obstructions: Troubleshooting Common Problems Close to the Point of Sample Injection ...
BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results